No. 2 Medical Innovation for 2020: Expanded Use of Minimally Invasive Mitral Valve Surgery
Expanded use of minimally invasive mitral valve surgery will be the No. 2 most influential medical innovation for 2020, predict experts at Cleveland Clinic.
No. 2 Medical Innovation for 2020: Expanded Use of Minimally Invasive Mitral Valve Surgery
FDA makes MitraClip available to more patients with mitral regurgitation
Since 2013, minimally invasive surgery for mitral valve repair has been available for patients with primary mitral regurgitation who can’t have open heart surgery. The innovative transcatheter MitraClip® device can bring relief to patients without the risk of conventional surgery.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Just five years later, researchers in the COAPT trial reported that MitraClip repair also showed significant benefits for patients with symptomatic mitral regurgitation secondary to heart failure. The transcatheter repair device reduced all-cause mortality and hospitalization compared with medical therapy.
In response, the FDA recently broadened its approval of the device, making minimally invasive repair an option for more people with mitral regurgitation.
In this video, learn more about why expanded use of minimally invasive mitral valve surgery is one of Cleveland Clinic’s Top 10 Medical Innovations for 2020.